# fda neurofibromatosis koselugo mek

The has approved the FIRST treatment for (#selumetinib) is a inhibitor used for the treatment of pediatric NF1 patients with plexiform neurofibromas. Koselugo was co-developed by AstraZeneca and Merck.

https://t.co/vXijxcHbug

13 50
2020-04-14